Search Results for:
-
Other News To Note
Noting that Octapharma has been cited for similar violations in the past, the FDA requested the company submit policies and procedures it intends to adopt to ensure its prescription drug promotions are in compliance, along with an explanation of how it expects the measures to succeedBioWorld Today | Wednesday, April 25, 2012 -
Other News To Note
The company said penetration to the hospital prescription drug market will provide guaranteed sales for the product, which is widely used in ChinaBioWorld International | Wednesday, April 25, 2012 -
Pharma: Other News To Note
The company said that penetration to the hospital prescription drug market will provide guaranteed sales for the product, which is widely used in ChinaBioWorld Today | Tuesday, April 24, 2012 -
SEC Looks for Public Guidance on JOBS Act
electronic sales aid designed for an iPad didn't pass muster with the FDA's Office of Prescription Drug Promotion (OPDPBy Mari Serebrov | BioWorld Today | Monday, April 16, 2012 -
FDA Submissions, Approvals & Other Actions: March 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, April 16, 2012 -
Senate Adds Investor Protection for Crowd Funding to JOBS Act
The agency got an ear full at a two-day public hearing last week as doctors, pharmacists, drugmakers and patient advocacy groups voiced their opinions on a proposed drug paradigm that would bridge between prescription drugs and over-the-counter (OTC) products by using technology to enable patients to self-diagnose and "prescribeBio Perspectives | Tuesday, March 27, 2012 -
Senate Adds Investor Protection for Crowd Funding to JOBS Act
The agency got an ear full at a two-day public hearing last week as doctors, pharmacists, drugmakers and patient advocacy groups voiced their opinions on a proposed drug paradigm that would bridge between prescription drugs and over-the-counter (OTC) products by using technology to enable patients to self-diagnose and "prescribeBy Mari Serebrov | BioWorld Today | Monday, March 26, 2012 -
Pricing Pressures on Rx Drugs Taking Root in U.S.
Overall spending on health care is expected to grow by 8.3 percent in 2014 (compared with 3.9 percent in 2010) due to those provisions, which are likely to increase the demand for prescription drugs and health care services, according to a study by the Centers for Medicare & Medicaid Services (CMSBy Mari Serebrov | BioWorld Insight | Monday, March 26, 2012 -
Growing State Patchwork Spurs Industry Tracking Proposal
Taking this immediate first step would help to ensure the efficient flow of prescription drugs between states, raise the bar for states...RxTec would then require manufacturers to apply an SNI, lot number and expiration date to prescription drugs at the unit and case levelsBy Mari Serebrov | BioWorld Today | Monday, March 12, 2012 -
FDA Submissions, Approvals & Other Actions: February 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Monday, March 12, 2012 -
Congress Seeks Answers to Growing Rx Drug Abuse
Such "powerful and seductive narcotic prescription drugs" shouldn't be used to treat a tooth ache or a sore knee, Rep...Rannazzisi, in turn, appealed to everyone in the prescription drug supply chain to police each otherBio Perspectives | Wednesday, March 7, 2012 -
Pediatrics Come up Short in Postmarket Requirements
standards for tracking and tracing prescription drugsBy Mari Serebrov | BioWorld Today | Tuesday, March 6, 2012 -
Congress Seeks Answers to Growing Rx Drug Abuse
Such "powerful and seductive narcotic prescription drugs" shouldn't be used to treat a tooth ache or a sore knee, Rep...Rannazzisi, in turn, appealed to everyone in the prescription drug supply chain to police each otherBy Mari Serebrov | BioWorld Today | Monday, March 5, 2012 -
CRS: Many Issues Could Trip Up PDUFA Reauthorization
The Feb. 22 warning letter, which stems from an inspection last July, also cited APP for marketing five unapproved prescription drugs...The agency is proposing an experimental study to assess how variations in corrective advertising may impact misleading beliefs about a prescription drugBy Mari Serebrov | BioWorld Today | Wednesday, February 29, 2012 -
FDA Submissions, Approvals & Other Actions: January 2012
PDUFA = Prescription Drug User Fee ActBioWorld Insight | Tuesday, February 21, 2012 -
Vernalis Inks Specialty Pharma Deal with Tris, Raises $103.8M
prescription drug market and also catapults the company's market capitalization from £20 million to £100 millionBy Nuala Moran | BioWorld International | Wednesday, February 15, 2012 -
Biopharma Fees to Shoulder FDA 2013 Budget Increase
In an effort to cut $302.8 billion from Medicare spending over the next decade, President Barack Obama wants to align Part D prescription drug rebates for low-income beneficiaries with those paid under Medicaid and strengthen the independent payment advisory board (IPABBio Perspectives | Tuesday, February 14, 2012 -
Biopharma Fees to Shoulder FDA 2013 Budget Increase
In an effort to cut $302.8 billion from Medicare spending over the next decade, President Barack Obama wants to align Part D prescription drug rebates for low-income beneficiaries with those paid under Medicaid and strengthen the independent payment advisory board (IPABBy Mari Serebrov | BioWorld Today | Tuesday, February 14, 2012 -
Vernalis Inks Specialty Pharma Deal with Tris, Raises £65.9M
prescription drug market and also catapults the company's market capitalization from £20 million to £100 millionBy Nuala Moran | BioWorld Today | Monday, February 13, 2012 -
Word on the Street
The Centers for Medicare & Medicaid Services proposed a rule relating to manufacturer rebates and alignment of pharmacy reimbursement rates for covered outpatient prescription drugsBioWorld Insight | Monday, February 6, 2012
Category
Current Filters
- xPrescription Drug
Related Keywords
Categories
- x BioWorld Today (780)
- x BioWorld Insight (141)
- x Bio Perspectives (45)
- x BioWorld International (38)
- x State of the Industry Report (24)
- x Top 25 Drug Report (13)
- x BioWorld Snapshots (4)
- x RNAi Report (1)
- x BioWorld Genomics Review (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.